Clinical Trials Logo

Clinical Trial Summary

Placenta accreta occurs when the placental implantation is abnormal. The marked rise in incidence has been assumed the increasing prevalence of cesarean delivery in recent years.


Clinical Trial Description

The most accepted theory is that abnormal placentation . The most important risk factor for placenta accreta is placenta previa after a prior cesarean delivery. The first clinical manifestation of placenta accreta is usually severe , life-threatening hemorrhage. The recommended intervention of suspected placenta accreta is planned preterm cesarean hysterectomy with the placenta left in situ. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03416296
Study type Observational
Source Aljazeera Hospital
Contact
Status Completed
Phase
Start date March 15, 2018
Completion date December 20, 2019

See also
  Status Clinical Trial Phase
Not yet recruiting NCT05817448 - Hypoxia-induced Autophagy in the Pathogenesis of MAP
Active, not recruiting NCT02784886 - Cell-free Fetal DNA Circulating in the Maternal Plasma as a Marker for Morbidly Adherent Placenta N/A
Recruiting NCT03676855 - Comparison Between Bladder Dissection Before and After Uterine Incision in Cesarean Section for Morbidly Adherent Placenta N/A
Withdrawn NCT02635412 - Delivery Timing in Morbidly Adherent Placentas: a Randomized, Controlled Trial N/A
Recruiting NCT04938050 - Diagnostic Accuracy of a Specialized Pro Forma in Assessing Morbidly Adherent Placenta With Correlation to Intra-operative Findings
Completed NCT03976453 - Psychological Outcome of Women With Morbidly Adherent Placenta Following Hystrectomy
Recruiting NCT05307016 - Morbidly Adherent Placenta, Diagnosis and Proper Management